UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis

Launched by NANJING IASO BIOTECHNOLOGY CO., LTD. · Jul 31, 2025

Keywords

ClinConnect Summary

This clinical trial is testing a new treatment called UB-VV410 for adults who have active systemic lupus erythematosus (SLE), including those with lupus nephritis (LN), which is when lupus affects the kidneys. The main goal is to find out if this treatment is safe, how well it works, and the best dose to use. The study will include two groups of people: those with active kidney inflammation caused by lupus and those with active lupus symptoms without kidney involvement. Researchers will carefully increase the dose to find the safest and most effective amount, and some participants may get more than one round of treatment if they don’t improve fully but are doing well with the medication.

To join the study, participants must be adults diagnosed with SLE for at least six months and show signs of active disease. People with serious infections, certain other medical conditions, or who are pregnant or breastfeeding won’t be eligible. If accepted, participants will receive the study drug through an IV (into a vein) and will be closely monitored for side effects and improvements. This study is not yet recruiting, but it aims to help find better treatment options for people with difficult-to-treat lupus.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 at time of consent.
• • 2. Provide voluntary written informed consent.
• • 3. Documented medical records indicated SLE diagnosis or diagnosis of SLE according to the 2019 EULAR/ACR classification criteria for SLE for at least 6 months.
• • 4. Current or history of elevated anti-dsDNA and/or elevated anti-Smith antibody.
• • 5. Alanine aminotransferase (ALT) ≤ 2.5 × ULN, aspartate aminotransferase (AST) ≤ 2.5 × ULN, AND total bilirubin \< 1.5 × ULN (or AST, ALT, and alkaline phosphatase \< 5 × ULN, and total bilirubin ≤ 3 × ULN for subjects with Gilbert's syndrome
• • 6. No ongoing coagulopathies requiring periodic replacement of clotting factors (eg, fresh frozen plasma, cryoprecipitate). Note: Subjects on a stable anticoagulant regimen \> 6 months with activated partial thromboplastin time (APTT) ≤ 2.5 × ULN and international normalized ratio (INR) \> 2 and \< 3 are allowed on study.
• • 7. No serious concomitant diseases or active/uncontrolled infections.
• • 8. For LN-specific subjects: Active, biopsy-proven, proliferative LN with the classification of Class III or Class IV according to the 2018 revised ISN/RPS criteria. Note: Overlapping Class V is allowed.
• • 9. For Non-LN SLE-specific subjects: SLEDAI-2K score of ≥ 8 (including at least 4 points from non-laboratory assessments; ) and at least 2 BILAG B organ system scores, and/or at least 1 BILAG A organ system score, including, but not limited to, cardiac (peri- or myocarditis), respiratory (pleuritis or lung involvement), vascular, hematological and musculoskeletal.
• Exclusion Criteria:
• • 1. Women who are pregnant or breastfeeding.
• • 2. BILAG A for neuropsychiatric SLE.
• • 3. Any acute, severe lupus-related flare that needs immediate treatment, such as acute pericarditis, catastrophic antiphospholipid syndrome, or acute CNS lupus (eg, psychosis, seizure).
• • 4. Diagnosis of drug-induced SLE rather than idiopathic SLE.
• • 5. Receiving hemodialysis or peritoneal dialysis.
• • 6. History of previous bone marrow transplantation, gene therapy, adoptive cell transfer, or any kind of CAR T-cell therapy.
• • 7. History of or active human immunodeficiency virus (HIV) infection.
• • 8. Active hepatitis B (HepB) or hepatitis C (HepC). Note: Subjects with negative HepB virus DNA or a negative HepC virus RNA assay for viral load quantifications are permitted. Additionally, subjects who are positive for HepB surface antigen and/or anti-HepB core antibody with a negative HepB virus DNA are eligible.
• • 9. Allergies to supportive medications required for CAR T-cell toxicity management (eg, tocilizumab).
• • 10. Ongoing CNS diseases (eg, seizure disorder, tremor, history of cerebral vascular accident \[CVA\]/recurrent transient ischemic attack \[TIA\], cerebritis, substantial psychiatric disorder) that would preclude evaluation of immune effector cell-associated neurotoxicity syndrome (ICANS).
• • 11. Serious and/or uncontrolled medical condition that, in the Investigator's judgment, would cause an unacceptable safety risk, interfere with study procedures or results, or compromise compliance with the protocol.
• • 12. Major surgery within 12 weeks prior to administration of UB-VV410 or plans to undergo major surgery during the trial period and whom the Investigator considers to be at unacceptable risk.
• • 13. Actively receiving treatment in other interventional clinical trials. Note: continued follow-up on previous trials is allowed for survivorship, but no further investigational agents or assessments will be allowed.